# NCT05104866 (NCT05104866)

> A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05104866
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer
- Interventions: Dato-DXd; Capecitabine; Gemcitabine; Eribulin; Vinorelbine
- Enrollment: 732
- Primary outcome: Progression-Free Survival
- Primary outcome: Overall Survival

## Commentary we found

- X threads: 79
- YouTube: 76
- Podcasts: 64

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05104866

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05104866", "email": "<work email>"}; the inbox owner confirms by the emailed link.